27 results on '"Ailawadhi S"'
Search Results
2. 209MO Impact of CMV reactivation on survival and relapse following allogeneic stem cell transplantation for de novo myeloid sarcoma
3. Real-World Utilization of Radiation Therapy (RT) in Multiple Myeloma (MM): An Analysis of the Connect® MM Registry
4. P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
5. S171: MOLECULAR CLUSTERS OF IGM MONOCLONAL GAMMOPATHIES PRESENT DISTINCT BIOLOGIC, IMMUNE AND METABOLIC FEATURES
6. 857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)
7. P1.12-08 The Impact of Patient Age and Socioeconomic Factors on Clinical Outcomes in Small Cell Lung Cancer (SCLC): A National Study
8. PS1384 TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY
9. P1.15-18 The Impact of Patient Age on Clinical Outcomes in NSCLC: A National Study
10. P2.06-24 The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA
11. Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry
12. OA 06.07 Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers
13. OA 06.05 Socioeconomic Factors Affecting Outcomes in Non-Small Cell Lung Cancer (NSCLC): A Large Population-Based Analysis
14. Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
15. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
16. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
17. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
18. Financial burden after allogeneic hematopoietic cell transplantation: a qualitative analysis from the patient’s perspective
19. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
20. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
21. Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management
22. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
23. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).
24. Erlotinib for metastatic non-small cell lung cancer (mNSCLC): First, second or third line setting—Does it matter? A single institution experience
25. Serotonin syndrome caused by interaction between citalopram and fentanyl
26. Intestinal Trefoil Factor (TFF3) expression and correlation with other signalling proteins in cholangiocarcinoma
27. Carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer receiving systemic chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.